NCT01083615 - A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Castrate-Resistant Prostate CancerHormone Refractory Prostate Cancer

Interventions

DRUG

custirsen sodium

An antisense oligonucleotide that blocks production of clusterin

DRUG

isotonic, 0.9% sodium chloride

Placebo for custirsen sodium

DRUG

docetaxel

DRUG

cabazitaxel

DRUG

prednisone

Trial Locations (33)

13210

Syracuse

21201

Baltimore

27607

Raleigh

29209

Columbia

33308

Fort Lauderdale

33612

Tampa

38120

Memphis

44718

Canton

48201

Detroit

61801

Urbana

64132

Kansas City

68130

Omaha

70006

Metairie

73120

Oklahoma City

75701

Tyler

89169

Las Vegas

91705

La Verne

96813

Honolulu

97239

Portland

01805

Burlington

R3E 0V9

Winnipeg

L8V 5C2

Hamilton

Unknown

Lyon

Paris

Saint-Herblain

Villejuif

Barcelona

Madrid

Pamplona

Sabadell

Valencia

Cambridge

Sutton